<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967340</url>
  </required_header>
  <id_info>
    <org_study_id>RC18_0351</org_study_id>
    <nct_id>NCT03967340</nct_id>
  </id_info>
  <brief_title>PREdiction of Chronic LUng Allograft Dysfunction</brief_title>
  <acronym>PRELUD</acronym>
  <official_title>PREdiction of Chronic LUng Allograft Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic lung allograft dysfunction (CLAD) is the leading cause of long-term mortality after
      lung transplantation. Several risk factors for CLAD have been identified, but the exact
      pathophysiology and triggering molecular factors remain largely unknown. Moreover, in
      clinical practice, no integration of the different risk factors is achieved. CLAD is
      therefore diagnosed most often late with the persistent decline in respiratory function,
      revealing a profound and irreversible alteration of the pulmonary graft. Several blood
      biomarkers that can predict the occurrence of CLAD more than 6 months before clinical
      diagnosis have been identified and validated. From these preliminary results, a composite
      score is being developed from independent samples from the COLT (COhort in Lung
      Transplantation) cohort. The main objective of this project is to validate this robust and
      predictive composite score (biological and clinical) of CLAD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MMP-9 levels in plasma, gene expression and lymphocyte levels in blood associated with Chronic Lung Allograft Dysfunction (CLAD)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression of the 3 genes BLK, POU2AF1 and TCL1A in whole blood associated with CLAD</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMP-9 levels over time associated with CLAD</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transitional B lymphocytes rate over time associated with CLAD</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T lymphocytes levels over time associated with CLAD</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Lung Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Lung transplant</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood and serum will be collected and retained in a biorepository
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients newly enrolled on the waiting list in transplant centres will be included in the
        PRELUD study.

        Based on the number of annual transplants in France (300/year), we plan to include 240
        patients at the time of their registration on the transplant waiting list. Of these 240
        patients, we estimate that 190 patients will be transplanted.

        It will be possible to include patients in emergencies. In this case, the consent of a
        trusted person or relative will be obtained and then the patient will give his or her
        consent as soon as his or her condition permits.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients to receive lung transplants awaiting registration on the transplant waiting
             list

          -  Patients affiliated to a social security system

          -  Patients who have given their informed consent

          -  Patients weighing more than 26 kg

          -  Patients over 16 years of age

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Patients unable to follow the protocol

          -  Patients with concomitant inflammatory diseases, regardless of acute, chronic or
             infectious rejection.

          -  Patients with a history of cancer in remission for less than 5 years, with the
             exception of localized skin cancers, excluding melanoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrien TISSOT, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrien TISSOT, Dr</last_name>
    <phone>0240165533</phone>
    <phone_ext>+33</phone_ext>
    <email>adrien.tissot@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Claire DROMER, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Claire DROMER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christophe PISON, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Christophe PISON, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Chirurgical Marie Lannelongue</name>
      <address>
        <city>Le Plessis-Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jérôme LE PAVEC, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Jérôme LE PAVEC, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean François MORNEX, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Jean François MORNEX, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Martine REYNAUD GAUBERT, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Martine REYNAUD GAUBERT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Adrien TISSOT, Sr</last_name>
    </contact>
    <investigator>
      <last_name>Adrien TISSOT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Hervé MAL, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Hervé MAL, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Romain KESSLER, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Romain KESSLER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine ROUX, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Antoine ROUX, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Aurélie LE BORGNE, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Aurélie LE BORGNE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic lung allograft dysfunction</keyword>
  <keyword>lung transplantation</keyword>
  <keyword>biomarkers</keyword>
  <keyword>personalized medecine</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

